tbuckley/cabot-search huggingface dataset:
McClellan Confirmed
Authors: Brian Vastag
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CBX7 is a tumor suppressor in mice and humans
Authors: Floriana Forzati, Antonella Federico, Pierlorenzo Pallante, Adele Abbate, Francesco Esposito, Umberto Malapelle, Romina Sepe, Giuseppe Palma, Giancarlo Troncone, Marzia Scarfò, Claudio Arra, Monica Fedele, Alfredo Fusco
Journal: Journal of Clinical Investigation (2012)
Silicosis Mortality, Prevention, and Control—United States, 1968-2002
Journal: JAMA (2005)

Silicosis is a preventable occupational lung disease caused by inhaling dust containing crystalline silica; no effective treatment for silicosis is available. Deaths from inhalation of silica-containing dust can occur after a few months' exposure (1). Crystalline silica exposure and silicosis have been associated with work in mining, quarrying, tunneling, sandblasting, masonry, foundry work, glass manufacture, ceramic and pottery production, cement and concrete production, and work with certain materials in dental laboratories. To describe patterns of silicosis mortality in the United States, CDC analyzed data from the National Institute for Occupational Safety and Health (NIOSH) National Occupational Respiratory Mortality System (NORMS) for 1968-2002. This report summarizes the results of that analysis, which indicated a decline in silicosis mortality during 1968-2002 and suggested that progress has been made in reducing the incidence of silicosis in the United States. However, silicosis deaths and new cases still occur, even in young workers. Because no effective treatment for silicosis is available, effective control of exposure to crystalline silica in the workplace is crucial.
Brown-Pearce Tumors
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Utility and Limitations of Claims Data
Authors: Jesse Green
Journal: Annals of Internal Medicine (1994)

Letters15 June 1994Utility and Limitations of Claims DataJesse Green, PhDJesse Green, PhDNew York University Medical Center; New York, NY 10016Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-120-12-199406150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The levels of under-reporting noted by Jollis and associates [1] impressively show the severe limitation of claims data in defining prognostic risk factors of patients with ischemic heart disease. More than half the patients with specific conditions were not identified as such by the claims data.In a recent coding audit of claims data collected by the State of California [2], we also found prognostic risk factors to be seriously under-reported. Applying the risk-adjustment model used by the Health Care Finance Administration for its annual hospital mortality release to the audited data, coding discrepancies led to a ...References1. Jollis JG, Ancukiewicz, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB. Discordance of databases designed for claims payment versus clinical information systems: Implications for outcome measurement. Ann Intern Med. 1993; 119:844-50. Google Scholar2. Green J, Wintfeld N. How accurate are hospital discharge data for evaluating effectiveness of care? Med Care. 1993; 31:719-31. Google Scholar3. Hsia DC, Krushat WM, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system. N Engl J Med. 1988; 318:352-5. Google Scholar4. Green J. Problems in the use of outcome statistics to compare health care providers. Brooklyn Law Review. 1992; 58:55-73. Google Scholar5. Dans PE. Looking for answers in all the wrong places (Editorial). Ann Intern Med. 1993; 119:855-7. Google Scholar Author, Article, and Disclosure InformationAuthors: Jesse Green, PhDAffiliations: New York University Medical Center; New York, NY 10016 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHealth Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA TreatmentHealth Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA TreatmentAssessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract InfectionsVariation of health-care resource utilization according to GERD-associated complications 15 June 1994Volume 120, Issue 12Page: 1049-1051KeywordsDeath ratesDiagnosis related groupsHealth careInformation storage and retrievalMedical risk factorsMedical staffMortalityMotivationQuality improvementResearch quality assessment ePublished: 15 August 2000 Issue Published: 15 June 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Diphtheritic Treatment.
Authors: O. Grothan
Journal: JAMA (1896)

St. Paul, Neb., Feb. 14, <h3>To the Editor:</h3> —In theJournalof Feb. 1, 1896, we notice an extract from the<i>New York Medical Journal</i>, entitled "Diphtheria<i>sine</i>Antitoxin," credited to Dr. O. B. Douglas. We read this short article with much interest, as it seems to be very nearly a concise reproduction, in meaning at least, of a paper contributed by myself on the treatment of diphtheria, to the<i>Southwestern Medical Gazette</i>for March, 1887, from which the following is quoted. In speaking of the local application of irritants such as tine, ferri chlorid, we said: "In the first place we get the irritating effect on the diphtheritic abraded surfaces of the fauces and pharynx, which is anything but desirable, as it aggravates the inflammation by its constringent and irritative properties." "I have used locally a very mild gargle or spray of glycerin, carbolic acid and rosewater." "To sum
Plasminogen activators in human colorectal neoplasia
Authors: J S K Gelister, M R Lewin, M Mahmoud, P J Gaffney, P B Boulos
Journal: BMJ (1986)

A crucial step in the transition from adenomatous polyp to invasive colorectal cancer is the degradation of the epithelial basement membrane.Plasminogen activators may play a part in regulating the extracellular protease environment necessary for this to occur.Both functional and antigenic activity of the two principal activators ofplasminogen, tissue plasminogen activator and urokinase, were measured in 30 colorectal cancers, matched samples of mucosa, and eight adenomatous polyps.Both polyps (p<0-01) and carcinomas (p<0c001) had raised urokinase activities compared with normal mucosa, the activity being highest in the carcinomas.Activity of tissue plasminogen activator, however, was diminished in both polyps (p<0-01) and carcinomas (p<0001) compared with normal mucosa, the values being lowest in carcinomas.Plasmin generation by urokinase-in contrast with tissue plasminogen activator-is fibrin independent and thus less subject to physiological control.
Thirteenth Congress of the International Society for Research on Civilization Diseases and on Environment
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Thirteenth Congress of the International Society for Research on Civilization Diseases and on Environment Get access JNCI: Journal of the National Cancer Institute, Volume 78, Issue 6, June 1987, Page 1254, https://doi.org/10.1093/jnci/78.6.1254-a Published: 01 June 1987
Error in Byline
Journal: JAMA Neurology (2015)

H. Orhan Akman, PhD; Or Kakhlon, PhD; Jorida Coku, MS; Lorenzo Peverelli, MD; Hanna Rosenmann, PhD; Lea Rozenstein-Tsalkovich, BSc; Julie Turnbull, PhD; Vardiella Meiner, MD; Liat Chama, BSc; Israela Lerer, PhD; Shoshi Shpitzen, MS; Eran Leitersdorf, MD; Carmen Paradas, MD; Mary Wallace, LD, CCRC; Raphael Schiffmann, MD; Salvatore DiMauro, MD; Alexander Lossos, MD; Berge A. Minassian, MD
Appendix
Authors: Prezioso Piccirillo, Usai Pili, P Ospedale, S Trinità, Cagliari Zattoni, F Galassi, Polito Polito, M Jr, Azienda Ospedale, Umberto °ancona Gentile, M Di, Martino Asl N°, Di Avellino, Avellino Selvaggi, F Gesmundo, Martorana Bertaccini, Cosciani Cunico, S Panizza, Castello Tuveri, M Casa, Di Cura, S Cagliari, Morgia Falsaperla, Catuogno Romano, G Ospedale Civile ', G Jazzolino' Vibo, Valentia Catanzaro, Pirritano Nisticò, F Ospedale ', A Pugliese-Ciaccio', Catanzaro Comeri, G Paulesu, Carini Balloni, F Ospedale, S Annunziata, Asl Di, Firenze Antella -Bagno, Rizzo Gacci, Ricci Barbini, V Rosati, A Irccs, Osp Casa, Sollievo Sofferenza', S Rotondo, Miano Sebastiani
Journal: European Urology (2001)
Sex education in the inner city. Learning and retention
Authors: M. D. Benson
Journal: JAMA (1986)

The Discovery program, initiated in 1982, includes two separate one-hour presentations on sex education. It is presented by medical student volunteers to children in the seventh and eighth grades of inner-city public schools. A study including 1,133 youngsters demonstrated a 32% improvement in scores with excellent retention. A control group of 126 students tested three times who did not hear the program demonstrated no learning from the test alone. Socioeconomic status, grade, and sex all influenced the level of knowledge prior to instruction but did not affect the degree of learning. Searches of the medical and educational literature reveal that this appears to be the most thoroughly investigated sex education course in the United States for any grade level. In view of its low cost and ease of implementation, the program could well serve as a model for junior high school sex education curricula in other school systems. (<i>JAMA</i>1986;255:43-47)
Initial Choice of Antidepressant Therapy in Primary Care-Reply
Authors: Gregory E. Simon
Journal: JAMA (1996)

<h3>In Reply.</h3> —We agree with Dr Bruhat and colleagues that our findings may not necessarily generalize to older primary care patients. It is possible that adverse effects of TCAs might prove more problematic in the elderly. Our sample of elderly patients was not large enough to permit subgroup analyses. Dr Schwab raises a question not addressed in our study. While SSRI drugs are less toxic in overdose, our sample was not large enough to examine differences in morbidity, mortality, or cost attributable to suicide attempts. It is unlikely that any randomized trial will ever allow the statistical power necessary to address this question. The antidepressant cost information Schwab presents may not reflect the actual costs of prescribing. The "true" cost of initial antidepressant selection must reflect the complexity of actual antidepressant use (eg, medication switches, early discontinuation, or dosage actually consumed). Cost projections based on per-pill prices also require assumptions about "equivalent"
THE FIRST PHYSICIAN
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FOR THE AID AND COMFORT OF SUFFERING SOLDIERS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dermatology
Authors: Jeffrey S. Dover
Journal: JAMA (1994)

Since 1976, when<i>Propionibacterium acnes</i>was demonstrated to be uniformly sensitive to the antibiotics used in the treatment of acne, an increasing number of patients with antibiotic-resistant propionibacteria have been described. In a recent British study,<sup>1</sup>cultures of propionibacteria were taken from 468 patients with acne. All patients had received courses of antibiotics in the past; 155 patients had acne that was unresponsive to treatment for at least 3 months. Nearly half of the 468 patients had propionibacteria strains that were resistant to one or more antibiotics; erythromycin resistance was most common (124 patients). All 61 patients with propionibacteria strains that were resistant to tetracycline also showed resistance to doxycycline, but none showed resistance to minocycline. Twenty-seven patients had two or more propionibacteria strains with different antibiotic resistances. The patients who showed a response to antibiotics in this study did not harbor antibiotic-resistant propionibacteria strains. To avoid the problem
Operative Gynecology
Authors: John W. Huffman
Journal: JAMA (1970)

Twenty years ago no progressive gynecologist or general surgeon would have been without a copy of Te Linde's<i>Operative Gynecology</i>. Residents studied it before going into the operating room, and specialists taking their board examinations honed their wits on it. Because previous editions are held in such esteem by older gynecologists, any criticism of the present one is almost like stoning a sacred shrine. Unfortunately, however, this edition does not have the pertinence of its predecessors. The book is a very personal record of the techniques used on Dr. Te Linde's service at Johns Hopkins. Young men, well trained at other institutions, are likely to look askance at a regimen that keeps patients on liquid diets for a week postoperatively, that routinely uses stay sutures in closing laparotomy wounds, and that hospitalizes all patients for 14 days after hysterectomy. Almost every gynecological operation, from outmoded and discredited procedures to modern
Letter to the Editor: Predicting Postoperative Liver Dysfunction Based on Blood‐Derived MicroRNA Signatures
Authors: Jiangfa Li
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To the Editor: We read with interest the study of Starlinger et al.1 evaluating the ability of microRNA signatures to predict postoperative liver dysfunction in patients with liver cancer. The results showed that it could effectively predict postoperative liver dysfunction. After reading the article carefully, we have some suggestions to point out. First, their conclusions showed that preoperative microRNA signatures as a single indicator can effectively predict postoperative liver dysfunction.1 However, there are many factors affecting liver function after hepatectomy, including preoperative, intraoperative, and postoperative factors.2 A single preoperative indicator may be difficult to fully and effectively project postoperative liver function, especially for patients with cirrhosis. We believe that microRNA signatures can be used as a good indicator for evaluation of preoperative liver function and prediction of the patient's tolerance to maximum hepatectomy volume. Second, in the multivariate analysis of their study, patients were divided into major and minor groups only on the basis of hepatectomy volume in three segments, and future liver volume was used in Predictive Value of Preoperative Liver Function Tests. Liver volume is an important factor affecting postoperative liver function recovery.3 Standard residual liver volume (SRLV) and future liver remnant function (FLRV) can effectively predict the occurrence of postoperative liver dysfunction,4 whereas liver resection volume and future liver volume are not effective. We believe that the results of this study may be more interesting if the study includes SRLV or FLRV. Generally speaking, if combined with intraoperative and postoperative indicators, the results of this study would be more interesting and credible.
A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).
Authors: Carey K. Anders, Rashmi Krishna Murthy, Erika Paige Hamilton, Virginia F. Borges, David A. Cameron, Lisa A. Carey, Volkmar Müller, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobagyi, Ian E. Krop, Sibylle Loibl, Xavier B. Pivot, Mark D. Pegram, Dennis J. Slamon, Sara A. Hurvitz, Michaela L. Tsai, Eric P. Winer
Journal: Journal of Clinical Oncology (2017)

TPS1107 Background: Tucatinib (ONT-380) is a highly selective small molecule inhibitor of HER2 kinase with nanomolar potency. Unlike dual HER2/EGFR agents, it does not inhibit EGFR at clinically relevant concentrations, decreasing the potential for EGFR-related toxicities (severe skin rash and diarrhea). In preclinical studies, tucatinib demonstrated synergistic activity with Tz, and was active in HER2+ models of brain metastases (mets). In a Phase 1b study, tucatinib was combined with C and Tz in pts with HER2+ MBC previously treated with trastuzumab emtansine (T-DM1) and Tz. Objective responses were seen, including in pts with brain mets. The combination was well tolerated, with low rates of Gr 3 diarrhea at the recommended dose (300 mg PO BID, equivalent to the single agent MTD). Based on these data, tucatinib is now being evaluated in a study in combination with C and Tz (HER2CLIMB). Methods: The primary study objective is to assess the effect of tucatinib vs. placebo given with C + Tz on progression-free survival (PFS) based on independent central review. Additional objectives include PFS in patients with brain mets, overall survival, ORR, duration of response, clinical benefit rate, and safety. The study population includes adult patients with progressive HER2+ locally advanced or MBC who have had prior treatment with a taxane, Tz, pertuzumab and T-DM1. Patients with brain mets, including untreated or progressive brain mets, may be enrolled. 480 patients will be enrolled in North America, Europe, Israel, and Australia. Patients are receiving C (1000 mg/mg 2 PO BID for 14 days of a 21-day cycle) and Tz (6 mg/kg IV once every 21 days), and are being randomized in a 2:1 ratio to tucatinib 300 mg PO BID or placebo. Patients with isolated CNS progression may continue on study treatment after undergoing local CNS therapy. An independent Data Monitoring Committee is monitoring patient safety. Clinical trial information: NCT02614794.
Primary aldosteronism.
Journal: BMJ (1980)

and zinc compounds12 among the less toxic front runners.These do not share the side effects of existing antirheumatoid drugs, which suggests that combination treatment or successive use of a series of these compounds may be worth tryingand might even lead to earlier and more convincing remission.1 Wilkins RF, Segre EJ.Combination therapy with naproxen and aspirin in rheumatoid arthritis.
Massachusetts Medical Society
Authors: H. Quimby Gallupe
Journal: New England Journal of Medicine (1951)

AMERICAN MEDICAL ASSOCIATION MEMBERSHIP AND FELLOWSHIPThis question-and-answer explanation of the American Medical Association dues problem is divided into two sections.Prior to 1950Q. How did one become a member of the American Medical Association?A. By becoming a member of a district society one became a member of the state society and the American Medical Association.Q. Were there any American Medical Association membership dues?A. No.Q. Did a member receive the Journal of the American Medical Association? A. No.Q. How did one receive the Journal of the American Medical Association? A. By becoming a Fellow . . .